Literature DB >> 16283438

Cell-specific but p53-independent regulation of vascular endothelial growth factor expression by interferons in human glioblastoma cells.

Yongxue Yao1, Toshihiko Kubota, Kazufumi Sato, Hiroaki Takeuchi, Yuji Handa, Shigeru Matsukawa.   

Abstract

Vascular endothelial growth factor (VEGF) is a key mediator of tumor angiogenesis. Interferons (IFNs) have been widely used in the treatment of malignant or recurrent gliomas with only marginal benefit. The association between IFNs and VEGF expression remains unclear and should be an intensively investigated subject. The present study therefore examined the effects of different types of IFNs on VEGF expression in human T98G, A172 and U251 glioblastoma cells by quantitative RT-PCR and ELISA. Both type I (alpha, beta) and type II (gamma) IFNs upregulated VEGF expression in a cell-specific but p53-independent manner. Actinomycin D experiments demonstrated that IFNs did not alter VEGF mRNA stability. In contrast, induction of VEGF mRNA by IFNs was blocked by the protein synthesis inhibitor cycloheximide. Interestingly, cycloheximide also blocked IFN-induced activation of the p44/p42 mitogen-activated protein kinase, which was partially required for induction of VEGF by IFNs. These findings suggest that VEGF might be an indirect target gene of IFNs, and might provide insights into therapeutic applications of IFNs against angiogenesis-dependent tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16283438     DOI: 10.1007/s11060-005-6498-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

1.  High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer.

Authors:  P Salven; T Ruotsalainen; K Mattson; H Joensuu
Journal:  Int J Cancer       Date:  1998-04-17       Impact factor: 7.396

2.  A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.

Authors:  J C Buckner; P J Schomberg; W L McGinnis; T L Cascino; B W Scheithauer; J R O'Fallon; R F Morton; S A Kuross; J A Mailliard; A K Hatfield; J T Cole; P D Steen; A M Bernath
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

3.  Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways.

Authors:  Wei-Zhong Wu; Hui-Chuan Sun; Yue-Fang Shen; Jie Chen; Lu Wang; Zhao-You Tang; George Iliakis; Kang-Da Liu
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-11       Impact factor: 4.553

4.  Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development.

Authors:  Y K Hong; D S Chung; Y A Joe; Y J Yang; K M Kim; Y S Park; W K Yung; J K Kang
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

5.  Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours.

Authors:  Y Yao; T Kubota; K Sato; R Kitai; H Takeuchi; H Arishima
Journal:  Acta Neurochir (Wien)       Date:  2001       Impact factor: 2.216

6.  Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

Authors:  Zofia von Marschall; Arne Scholz; Thorsten Cramer; Georgia Schäfer; Michael Schirner; Kjell Oberg; Bertram Wiedenmann; Michael Höcker; Stefan Rosewicz
Journal:  J Natl Cancer Inst       Date:  2003-03-19       Impact factor: 13.506

Review 7.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

8.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

9.  Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia.

Authors:  Amit Verma; Dilip K Deb; Antonella Sassano; Suman Kambhampati; Amittha Wickrema; Shahab Uddin; Mani Mohindru; Koen Van Besien; Leonidas C Platanias
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

10.  Thymidine phosphorylase is angiogenic and promotes tumor growth.

Authors:  A Moghaddam; H T Zhang; T P Fan; D E Hu; V C Lees; H Turley; S B Fox; K C Gatter; A L Harris; R Bicknell
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

View more
  1 in total

1.  Dual effect of serum amyloid A on the invasiveness of glioma cells.

Authors:  Franciele Hinterholz Knebel; Renata Chaves Albuquerque; Renato Ramos Massaro; Silvya Stuchi Maria-Engler; Ana Campa
Journal:  Mediators Inflamm       Date:  2013-02-25       Impact factor: 4.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.